Our programs are directed at treating metabolic diseases to minimize their long-term complications through end-organ protection.
| PROGRAM |
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
|
PARTNER | TERRITORY |
|---|---|---|---|
|
Type 1 Diabetes
|
|
|
|
|
Dementia with Diabetes
|
|
|
|
|
Cystic Fibrosis Related Diabetes (CFRD)
|
|
|
|
|
Undisclosed
|
|
|
|
| Partnered Programs | |||
|
Type 2 Diabetes
|
|
Asia (*ROW retained)
|
|
|
Fatty Acid Oxidation Disorders
|
|
Worldwide
|
|
|
COPD
|
|
Asia (*ROW retained)
|
